IQVIA Holdings Inc. $IQV Stock Sold by Ieq Capital LLC

Ieq Capital LLC cut its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 4.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 84,842 shares of the medical research company’s stock after selling 3,545 shares during the quarter. Ieq Capital LLC owned 0.05% of IQVIA worth $22,810,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. bought a new position in IQVIA in the 2nd quarter worth $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in IQVIA by 9.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock worth $315,772,000 after buying an additional 134,997 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of IQVIA by 4.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock worth $282,657,000 after purchasing an additional 66,643 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of IQVIA during the second quarter valued at approximately $240,911,000. Finally, Bank of America Corp DE purchased a new stake in IQVIA in the 2nd quarter worth $235,551,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 4,446 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the completion of the sale, the insider owned 24,989 shares of the company’s stock, valued at approximately $6,967,682.87. This trade represents a 15.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.70% of the stock is currently owned by company insiders.

IQVIA Stock Down 3.0%

IQVIA stock opened at $250.21 on Friday. The business has a fifty day moving average of $267.34 and a two-hundred day moving average of $212.35. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 2.18. The firm has a market cap of $41.23 billion, a P/E ratio of 30.40, a P/E/G ratio of 2.29 and a beta of 1.16. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $284.50.

IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. The business had revenue of $4.43 billion for the quarter, compared to the consensus estimate of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The business’s revenue was up 8.0% compared to the same quarter last year. During the same period last year, the business posted $3.00 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Mizuho raised their price target on IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. Barclays upped their price target on shares of IQVIA from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. BMO Capital Markets raised their price target on IQVIA from $270.00 to $305.00 in a research note on Monday, October 19th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, September 12th. Finally, Royal Bank Of Canada raised their price objective on IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $294.21.

Read Our Latest Stock Analysis on IQVIA

IQVIA Company Profile

(Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

Recommended Stories

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.